PharmaVoice

JULY 8, 2025

This slow and steady concept gained more validation in June when the company announced early but promising data from a phase 2 trial of its MEK inhibitor atebimetinib combined with chemotherapy, which showed a six-month 94% overall survival in pancreatic cancer. You can unsubscribe at anytime. Sign up A valid email address is required.

Immunization

Pharmaceutical Technology

JULY 1, 2025

Takeda anticipates commencing commercialisation efforts for Gammagard liquid ERC in the US by 2026, with plans to follow suit in the European Union (EU) by 2027. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Sign up for our daily news round-up!

FDA

STAT

NOVEMBER 12, 2024

The medicine, Dato-DXd, is a type of next-generation chemotherapy called an antibody-drug conjugate that AstraZeneca and other companies are investing in heavily.   AstraZeneca had to resubmit a closely watched medicine for U.S.  Finally, AstraZeneca plans to invest $3.5 Continue to STAT+ to read the full story…

Chemotherapy